Studies suggest that analyzing Smad4 protein expression in pancreatic cancer cell lines can reveal insights into the molecular mechanisms driving pancreatic cancer, offering avenues for novel therapeutic strategies targeting Smad4-deficient tumors, to improve patient outcomes. This evidence concerns the gene SMAD4 and pancreatic neoplasm.